Tremfya (guselkumab) - Indicated for active psoriatic arthritis
Xeljanz (tofacitinib) - Indicated for active polyarticular course juvenile idiopathic arthritis for children aged 2 years and older
Simponi Aria (golimumab) - New indication for active polyarticular course juvenile idiopathic arthritis in children aged 2 years and older; additionally, indication for psoriatic arthritis extended to include patients aged 2 years and older
Ilaris (canakinumab) - Treatment of active Still disease, including adult onset
Taltz (ixekizumab) - New indication for active nonradiographic axial spondyloarthritis with objective signs of inflammation
Cosentyx (secukinumab) - Also approved for nonradiographic axial spondyloarthritis
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: FDA Approvals, Highlights, and Summaries: Rheumatology - Medscape - Feb 24, 2021.